MedTrace Logo

Treatment of Overactive Bladder With Anticholinergic Agents

NCT07046156 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-07-01

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Conditions

Interventions

DRUG

Oxybutynin Cl

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

DRUG

propiverine

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

DRUG

Tolterodine

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Sponsors & Collaborators

  • Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

    lead OTHER

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2025-06-30
Completion
2026-06-01
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07046156 on ClinicalTrials.gov